$495 Million is the total value of Avoro Capital Advisors LLC's 44 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 48.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $33,136,000 | -14.7% | 400,000 | -4.7% | 6.69% | -1.8% |
TSRO | Sell | TESARO INC | $31,159,000 | +11.9% | 231,700 | -16.6% | 6.30% | +28.9% |
SRPT | Sell | SAREPTA THERAPEUTICS INC | $27,713,000 | -67.1% | 1,010,300 | -26.3% | 5.60% | -62.1% |
DERM | Sell | DERMIRA INC | $23,224,000 | -14.8% | 765,709 | -5.0% | 4.69% | -1.9% |
BMY | Sell | BRISTOL MYERS SQUIBB CO. | $16,655,000 | -22.8% | 285,000 | -28.7% | 3.36% | -11.0% |
AKBA | Sell | AKEBIA THERAPEUTICS INC | $8,656,000 | +1.3% | 831,515 | -12.0% | 1.75% | +16.6% |
SRNE | Sell | SORRENTO THERAPEUTICS INC | $7,135,000 | -39.8% | 1,456,056 | -4.9% | 1.44% | -30.7% |
VCYT | Sell | VERACYTE INC | $7,020,000 | +0.4% | 906,999 | -1.3% | 1.42% | +15.6% |
VNDA | Sell | VANDA PHARMACEUTICALS INC | $6,084,000 | -55.8% | 381,466 | -53.9% | 1.23% | -49.2% |
FBIO | Sell | FORTRESS BIOTECH INC | $3,241,000 | -19.6% | 1,200,342 | -11.5% | 0.66% | -7.4% |
CRVS | Sell | CORVUS PHARMACEUTICALS INC | $3,098,000 | -29.8% | 216,619 | -19.3% | 0.63% | -19.2% |
Sell | PERNIX THERAPEUTICS HOLDINGS INCconvertible debt | $1,479,000 | -27.9% | 6,000,000 | -14.3% | 0.30% | -16.9% | |
Sell | TRILLIUM THERAPEUTICS INC | $1,285,000 | -72.5% | 227,399 | -28.0% | 0.26% | -68.3% | |
DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -46,082 | -100.0% | -0.05% | – |
NK | Exit | NANTKWEST INC | $0 | – | -72,412 | -100.0% | -0.10% | – |
VCEL | Exit | VERICEL CORP | $0 | – | -215,744 | -100.0% | -0.11% | – |
CEMP | Exit | CEMPRA INC | $0 | – | -30,000 | -100.0% | -0.13% | – |
OMED | Exit | ONCOMED PHARMACEUTICALS INC | $0 | – | -85,000 | -100.0% | -0.17% | – |
VSAR | Exit | VERSARTIS INC | $0 | – | -95,742 | -100.0% | -0.21% | – |
INNL | Exit | INNOCOLL HOLDINGS PLCshares | $0 | – | -468,148 | -100.0% | -0.48% | – |
PTI | Exit | PROTEOSTASIS THERAPEUTICS INC | $0 | – | -179,565 | -100.0% | -0.49% | – |
SRPT | Exit | SAREPTA THERAPUTICS INCcall | $0 | – | -190,000 | -100.0% | -1.06% | – |
AGIO | Exit | AGIOS PHARMACEUTICALS INC | $0 | – | -150,000 | -100.0% | -1.39% | – |
CASC | Exit | CASCADIAN THERAPEUTICS INC | $0 | – | -5,611,323 | -100.0% | -1.62% | – |
GWPH | Exit | GW PHARMACEUTICALS PLCads | $0 | – | -133,600 | -100.0% | -3.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
ARGENX SE | 26 | Q3 2023 | 9.5% |
IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G/A | 2024-04-23 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.